The biotech says that the cell-penetrating nature of the peptides, when ... unveiled Wednesday at the virtual San Antonio Breast Cancer Symposium.
News
- RA Capital backs Oxford spinout PepGen with a $45M Series A, seeking to treat Duchenne and ...
- PharmAbcine presents the latest data of the ongoing Phase Ib mTNBC trial at SABCS 2020
The results were presented at the SABCS (San Antonio Breast Cancer ... PharmAbcine is a clinical-stage biotech company focusing on the ...
- BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®
("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB: BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for ...
- Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio Breast Cancer ...
... ongoing Phase 1/2 clinical trial for BDC-1001 in patients with HER2-expressing solid tumors at the San Antonio Breast Cancer Symposium (SABCS) ...
- Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional ...
... at the San Antonio Breast Cancer Symposium (SABCS) 2020 Virtual Meeting. ... About Evelo Biosciences Evelo Biosciences is a clinical stage ...